Mina Dehbid, Seyed Ahmad Aleyasin and Hamidreza Vaziri
Background: Recent findings indicate epigenetic modifications as key factors in breast carcinogenesis. The abnormal methylation patterns of genes are among the consequences of epigenetic changes. The DNA methylation is involved in the regulation of gene activity and abnormal DNA methylation is associated with various diseases, including cancer. Due to the importance of epigenetics in cancer, particularly breast cancer, it seems to perform the most effective methods of prediction, detection and tracking of recurrence, and the availability of suitable biomarkers. In this study, the MAP9 (Microtubule-Associated Protein 9) gene methylation was examined as an epigenetic biomarker of cancer.
Methods: We evaluated 30 breast cancer samples and 30 normal samples to identify diagnosis biomarkers for breast cancer. Sample of breast cancers were identified, with different Clinical and pathological data, which might be related with changes in MAP9 gene methylation. DNA was extracted from whole blood of breast cancer patients and healthy samples. The methylation-sensitive restriction enzymes were used to identify methylated site in epigenetic marker. Methylation-sensitive enzyme cannot cut hypermethylated sequences. Methylation-sensitive enzyme is not capable of cutting sequences of MAP9 gene, thus replication occurs.
Results: MAP9 gene is significantly hypermethylated in breast cancer (P<0.05). Moreover the results of this study indicated that there was no relation between stage of disease, age of patients, Estrogen Receptor (ER), Progesterone Receptor (PR), and human epidermal growth factor 2 (HER2) status and the methylation of MAP9 gene in breast cancer samples (P>0.05).
Conclusion: In this study indicated MAP9 gene methylation changes in breast cancer and it can be used as molecular biomarker for breast cancer diagnosis.
Teile diesen Artikel
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi 